Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Panbela Therapeutics, Inc. (PBLA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.2703-0.0887 (-24.71%)
At close: 04:00PM EDT
0.2690 -0.00 (-0.48%)
After hours: 05:57PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3590
Open0.2501
Bid0.2607 x 800
Ask0.2703 x 800
Day's Range0.2501 - 0.3012
52 Week Range0.2030 - 2.4000
Volume1,811,734
Avg. Volume593,166
Market Cap3.631M
Beta (5Y Monthly)0.40
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Panbela Announces Pricing of Approximately $6 Million Public Offering

    MINNEAPOLIS, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela” or the “Company”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the pricing of a public offering of (i) 20,100,000 shares of its common stock (or pre-funded warrants in lieu thereof) and (ii) warrants to purchase up to 30,150,000 shares of its common stock (the “Public Warrants”) at a purchase price of

  • GlobeNewswire

    Panbela Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

    MINNEAPOLIS, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced Regulatory approval for the opening of trial sites in Spain, France and Italy for Panbela’s clinical trial in the first-line treatment of metastatic pancreatic cancer. ASPIRE is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in

  • GlobeNewswire

    Panbela Provides Business Update and Reports Q2 2022 Financial Results

    MINNEAPOLIS, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2022. Management is hosting an earnings conference call today at 4:30 p.m. ET. The second quarter was marked by meaningful progress. Q2 and Recent Highlights: First Patient Enrolled in its Aspi

Advertisement
Advertisement